Actuate Therapeutics Announces Plans to Expand Clinical Pipeline, Advancing Elraglusib Tablet into a Phase 1/2 Clinical Program in Refractory Cancers
Actuate Therapeutics, Inc. - Common stock (ACTU)
Company Research
Source: GlobeNewswire
-Initiation of phase 1 portion of the trial planned in 2H 2026 -Phase 2 portion of the trial will initiate development of the elraglusib tablet in specific indications, including refractory melanoma and additional target solid tumor and hematologic cancers -Program builds on early clinical evidence of monotherapy activity observed in immune checkpoint inhibitor (CPI)-refractory metastatic melanoma in a previously completed trial CHICAGO and FORT WORTH, Texas, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3ß), today announced plans to initiate a Phase 1/2 clinical program evaluating the oral tablet dosage form of elraglusib in patients with advanced cancer. The phase 1 portion of the planned Phase 1/2 program aims to determin
Show less
Read more
Impact Snapshot
Event Time:
ACTU
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACTU alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACTU alerts
High impacting Actuate Therapeutics, Inc. - Common stock news events
Weekly update
A roundup of the hottest topics
ACTU
News
- Actuate Therapeutics (NASDAQ:ACTU) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=ACTU&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StMarketBeat
- Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase 2 Trial Demonstrating Extended Long-Term Overall Survival Benefit with Elraglusib Plus Chemotherapy for Metastatic Pancreatic Cancer in Oral Presentation at ASCO GI Acquire Media Monitor
- Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase 2 Trial Demonstrating Extended Long-Term Overall Survival Benefit with Elraglusib Plus Chemotherapy for Metastatic Pancreatic Cancer in Oral Presentation at ASCO GI GlobeNewswire
- Actuate Therapeutics Announces Positive Patient Outcomes from Phase 1 Trial in Difficult-to-Treat Refractory Pediatric CancersGlobeNewswire
- Actuate Therapeutics (NASDAQ:ACTU) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
ACTU
Earnings
- 11/13/25 - Beat
ACTU
Analyst Actions
- 11/19/25 - HC Wainwright
ACTU
Sec Filings
- 1/12/26 - Form 8-K
- 1/7/26 - Form 4
- 12/17/25 - Form SCHEDULE
- ACTU's page on the SEC website